$LSAQ News
Last published 5y ago
- 5y agoLSAQSNCEScience 37, the Operating System for Agile Clinical Trials, Closes Business Combination with LifeSci Acquisition II Corp. and Will Begin Trading on Nasdaq as SNCEGlobeNewswireScience 37 to debut on Nasdaq as a publicly traded company under ticker symbol "SNCE" Business combination will provide Science 37 with approximately $235 million in cash proceeds to support continued growth Science 37 to fuel its mission to enable un
- 5y agoLSAQLifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business CombinationGlobeNewswireNEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ:LSAQ), a blank check company formed for the purpose of pursuing targets that are focused on healthcare innovation, today announced the confidential submission with the U.S
- 5y agoLOKBLSAQMFNCMNRMoore Kuehn Encourages MNR, LOKB, LSAQ and MFNC Investors to Contact Law FirmGlobeNewswireNEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to
- 5y agoLSAQScience 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the FutureBusiness WireTransaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and po
- 5y agoLSAQLifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public OfferingGlobeNewswireNEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public...